Biomarkers for Oncology
JH · Effective Oct 1, 2015
146 active Medicare policies list C25.9, and 20 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
Showing 100 of 146
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
J9 · Effective Apr 11, 2016
JH · Effective Dec 1, 2016
JL · Effective Dec 1, 2016
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
20 policies from 3 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Showing 10 of 16 · All Aetna policies
| Policy | Effective | Status of C25.9 |
|---|---|---|
| Bevacizumab for Non-Ocular Indications | Feb 20, 2024 | Covered |
| Brachytherapy | Jun 6, 2023 | Covered |
| Cryoanalgesia and Therapeutic Cold | Mar 16, 2023 | Covered |
| Endoscopic Ultrasonography | Feb 16, 2024 | Covered |
| Gonadotropin-Releasing Hormone Analogs and Antagonists | Jul 14, 2023 | Covered |
| Intraoperative Radiation Therapy (IORT) | Sep 22, 2023 |
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
J6 · Effective Apr 1, 2019
JK · Effective Apr 1, 2019
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J15 · Effective Aug 21, 2022
JE · Effective Aug 8, 2022
JF · Effective Aug 8, 2022
JJ · Effective Jul 3, 2022
JM · Effective Jul 3, 2022
J5 · Effective Jul 3, 2022
J8 · Effective Jul 3, 2022
J15 · Effective Dec 26, 2021
JE · Effective Jan 2, 2022
JF · Effective Jan 2, 2022
JJ · Effective Dec 26, 2021
JM · Effective Dec 26, 2021
J5 · Effective Dec 26, 2021
J8 · Effective Dec 26, 2021
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
JE · Effective May 17, 2020
JF · Effective May 17, 2020
JJ · Effective Feb 10, 2020
JM · Effective Feb 10, 2020
J5 · Effective Feb 9, 2020
J8 · Effective Feb 9, 2020
J15 · Effective Jul 27, 2020
JE · Effective Dec 26, 2022
JF · Effective Dec 26, 2022
JJ · Effective Feb 3, 2020
JM · Effective Feb 3, 2020
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J9 · Effective Oct 1, 2015
J6 · Effective May 1, 2017
JK · Effective May 1, 2017
J6 · Effective Jul 13, 2025
JK · Effective Jul 13, 2025
J9 · Effective Dec 12, 2021
JH · Effective Dec 12, 2021
JL · Effective Dec 12, 2021
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Nov 12, 2023
JM · Effective Nov 12, 2023
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Oct 1, 2015
J8 · Effective Oct 1, 2015
JJ · Effective Jun 12, 2017
JM · Effective Jun 12, 2017
JL · Effective Oct 1, 2025
J6 · Effective Apr 1, 2026
JL · Effective Apr 24, 2025
J9 · Effective Oct 1, 2025
National · Effective Oct 1, 2025
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J9 · Effective Oct 1, 2025
National · Effective Sep 27, 2026
National · Effective Mar 5, 2026
J9 · Effective Oct 1, 2025
J6 · Effective Oct 1, 2026
National · Effective Nov 16, 2023
| Covered |
| Magnetic Resonance Cholangiopancreatography | Feb 15, 2024 | Covered |
|---|
| Microwave Thermotherapy | Sep 19, 2023 | Covered |
|---|
| Pancreaticoduodenectomy (Whipple Resection) | Jun 5, 2023 | Covered |
|---|
| Panitumumab (Vectibix) | Feb 5, 2024 | Covered |
|---|
| Policy | Effective | Status of C25.9 |
|---|---|---|
| Cancer Antigen 125 Testing | Oct 1, 2026 | Covered |
| Cancer Antigen 19-9 Testing | Oct 1, 2026 | Covered |
| Carcinoembryonic Antigen Testing | Oct 1, 2026 | Covered |
| Policy | Effective | Status of C25.9 |
|---|---|---|
| Low-Level Laser and High-Power Laser Therapy | Mar 15, 2026 | Covered |